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Captopril is a selective inhibitor of angiotensin-converting 
enzyme (ACE) and is formulated by several pharmaceutical 
companies in Indonesia. This study was conducted to compare the 
bioavailability of a captopril tablet with reference products in 
healthy volunteers. The relative bioavailability of captopril was 
determined in single dose, randomized, crossover, and two-phase 
studies. The relative bioavailability of the test product (a generic 
captopril 50 mg tablet) with respect to the reference product was 
determined. Twelve healthy volunteers in two groups took part in 
these studies and took either the test or reference tablets in the 
first phase and received the other tablet in the second phase of 
each study. The bioavailability parameters include the peak 
concentration of captopril in serum (Cmax); the time to achieve 
the peak concentration (Tmax); and the area under the curve of 
captopril in serum versus time. Non-compartmental analysis on 
observed concentration versus time data has resulted in the mean 
value of Cmax of 545.26  22.90 ng/mL (test product) and 548.91 
 25.07 ng/mL (reference product) and mean Tmax of 1.13  0.08 
hours (test product) and 1.08  0.08 hours (reference product), 
mean of AUC0-7 value of 1820.51  75.31 ng. hour/mL (test 
product) and 1822.09  99.29 ng. hour/mL (reference product), 
and mean of AUC0-inf value of 1967.83  95.65 ng. hour/mL (test 
product) and 1996.94  124.52 ng. hour/mL (reference product). 
Based on the data, it can be concluded that there is no significant 
difference (p>0.05) in bioavailability between both captopril 
Tablet (test and reference product). 
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INTRODUCTION 
Captopril is the first orally active 
angiotensin-converting enzyme (ACE) inhibitor 
which is widely used antihypertensive drug. 
Angiotensin-converting enzyme is a peptidyl 
carboxypeptidase that catalyzes the conversion 
of angiotensin I to the active octapeptide 
angiotensin II in blood and other tissues, and 
may also reduce the degradation of bradykinin 
(Dollery, 1991; Jackson and Garrison, 1996). 
The drug is also used in the management of 
hypertension, in cardiac failure, following 
myocardial infarction (especially when there is 
ventricular dysfunction, even when this is mild), 
progressive renal insufficiency and in diabetic 
nephropathy (Parfitt and Martindale, 1999; 
Rang et al., 1999). Captopril also has 
antithrombotic effect by reducing venous 
thrombus  weight  in  rats.  The  mechanism  of  
antithrombotic action of captopril is dependent 
on the suppression of coagulation cascade and 
the enhancement of the fibrinolytic processes 
(Chabielska et al., 2005). 
In the body, approximately 68 to 76% of 
an oral dose is absorbed, and bioavailability of 
unchanged captopril is 62 – 65 %. Captopril is 
covalently bound to plasma protein. Peak  
blood levels are reached about an hour after an 
oral dose. The elimination half-life has               
been reported to be 1 to 2 hours, and 
elimination predominantly by renal excretion. 
Captopril is rapidly and extensively metabolized 
interaction involving its sulfhydryl group.           
Main pathway involves the formation of 
disulfide dimer of this drug as well as mixed 
conjugates with indogenous thiol-containing 
compounds and plasma proteins (Dollery, 
1991). 
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There are several clinical side effects of 
captopril including hypotension occurring in 
patients receiving it after the first dose, skin 
rash, cough  and  taste  disturbance  (dysgeusia). 
Captopril is contraindicated for patient with 
pregnancy, renal failure, the elderly and 
children. Therefore it is not recommended           
for these patients (Dollery, 1991; Jackson and 
Garrison, 1996). However, considering its           
side effects, administration of captopril must  
be monitored based on the benefit-risk            
ratio. Therefore, its pharmacokinetic data                
are important to ensure safety and product 
quality. 
The objective of this research was to 
evaluate the bioavailability of a 50 mg 
Indonesian Generic tablet of Captopril (test 
product) compared to that of a reference 
product. The pharmacokinetic parameters were 
used to describe the bioavailability of captopril 
in the body include the peak concentration of 
captopril in serum (Cmax); the time to achieve 
the peak concentration (Tmax); and the area 
under the curve of captopril in serum versus 
time. Other parameters such as mean residence 
time (MRT), half-time (t1/2), volume 
distribution at steady state (Vdss) and total 





The research had been carried out in 12 
healthy volunteers of both sexes, each 6 males 
and 6 females, aged between 20-40 years, 
weight of 40-60 kg, height around 150-170 cm. 
The volunteer’s body weight is about 70-150 % 
from ideal body weight versus body height 
(Suyono, 1996). The volunteers health were 
delineated from clinical and laboratory 
examination results, including a routine 
laboratory examination on the blood and urine, 
hepatic and renal function. These results were 
used to fulfill inclusion criteria of the study. An 
individual who was found to have renal failure, 
hepatic disease history, allergy to captopril and 
related compounds, or has smoking habit, 
drinking alcohol, was excluded from this 
research (exclusion criteria). At least within two 
weeks before this pharmacokinetic study has 
been commenced and during the research in 
progress, the volunteers were not allowed to 
consume any drugs. 
Before the research commenced, the 
volunteers were given explanation about the 
research (informed consent) and given 
opportunity to ask about it as much as possible. 
Moreover, each volunteer was asked to sign a 




Figure 1. Mean plasma captopril concentrations (n = 12) 
following single-dose administration of 1 x 50 mg reference 
product and Generic Captopril (test product) tablets. 
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During the research process, any 
complaint which was an indication the 
appearance of side effect obtained much 
attention and measures as good as possible by 
the medical doctor. The research protocol has 
obtained an ethical clearance from the Ethical 
Committee of Human Biomedical Research of 




Before the study was performed, each 
volunteer was asked to fast overnight. Drinking 
of plane water without sugar was allowed ad 
libitum. At 07.00 a.m. a blood sample (7.0 mL) 
was taken for a blank, and then was followed 
by drug administration orally with 50 mg dose 
of the test product (Generic Captopril 50 mg 
tablet) and the reference product (Capoten® 50 
mg tablet, Bristol-Myers Squibb). The blood 
samples were taken serially at 0.25; 0.5; 0,75; 1; 
1,5; 2; 3, 4; 5 and 7 hours using vacuntainer 
tubes. The serum was separated and stored in a 
freezer (-20C) in glass tubes at the upright 
position and were packed in aluminum foil (to 
avoid contact with rubber cover and photo 
decomposition) pending for the drug 
concentration analysis. Breakfast was given 4 
hours after the drug administration and the 
next meals were arranged after at the tenth 
hour taking sample. During the process of the 
research, each complaint on side effect 




Analysis was performed using high-
performance liquid chromatographic (HPLC) 
with UV detector (Jankowski et al., 1995). To 1 
mL serum in was added 30 L p-
bromophenacyl bromide 1 mg/mL in 
acetonitrile and also added 50 L NaOH 100 
mM. The mixture was left for 30 min. After 
adding 75 L HCl 1M, 150 L buffer acetate 
200 mM pH 4.0, extracted with 4 mL benzene. 
The mixture centrifuged 3000 rpm for 20 
menit. Its organic phase is moved into clean 
tube, and evaporated to dryness under nitrogen. 
The residue was reconstituted in 200 μL mobile 
phase and 20 μL was injected onto the HPLC 
column (LiChroCART 125-4 LiChrospher 
100 RP-18; 5 m). The mobile phase is mixture 
between acetonitril and 1 % acetic acid (6 : 4), 
with flow rate of 1.5 mL/min. Detection was at 
245 nm. The analytical method was fully 
validated in terms of linearity, accuracy and 
precision according to USP guidelines. 
 
Pharmacokinetic variables 
Some pharmacokinetic variables were 
calculated for each volunteer and product, 
using actual blood sampling times to compare 
the rate and extent of absorption of captopril in 
this study. The pharmacokinetic analysis from 
captopril serum concentrations versus time was 
performed using non-compartmental analysis 
(Benet and Galeazzi, 1979). The values of 
Cmax, Tmax were taken from the observed 
value of the drug concentration curve versus 
time of each volunteer. The areas under the 
plasma concentration curves (AUC0-t) were 
calculated using the linear trapezoidal rule. The 
value of MRT, t1/2, Vdss, and Cl were 
calculated using PK (Pharmacokinetic) 
Function software (Under Microsoft Excel). 
The pharmacokinetic parameter values of both 
captopril products were compared statistically 
using a paired t-test with a confidence level of 
95 % (SPSS program, 10.00 version).  
 
RESULT AND DISCUSSION 
Validation of the analytical method 
The method was linear over a range of 
20 – 800 ng/mL of drug in plasma. The 
method accuracy for concentrations ranging 
between 40 – 400 ng/mL and 500 ng/mL was 
80 –  90%, and the value of random analytical 
error was 5 – 7 %. The last value is parameter 
of inprecision of an analytical method. The 




Figure 1 shows an average concentration 
of captopril in serum versus time of 12 
volunteers, after the administration of a single 
dose of 50 mg Generic Captopril tablet (test 
product) and 50 mg reference tablets. From  
this figure it appears that the rates of 
absorption for both products were relatively 
similar after the drug administration. After 
reaching the peak, the curve decreased with 
rapid elimination.  
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The parameter values of captopril 
pharmacokinetics obtained after the 
administration of the two products are 
presented in tables II. The parameters used to 
evaluate the bioavailability of both products are 
captopril peak concentrations in serum (Cmax), 
the time required to achieve the peak 
concentrations (Tmax), and area under the 
curve of captopril concentration in serum 
versus time (AUC). 
From the observed captopril 
concentration in serum versus time and the 
pharmacokinetic values in 12 healthy volunteers 
after the administration (50 mg; oral) of 
Generic Captopril and reference product, the 
following results indicated that the mean AUC0-
7 value of Generic Captopril tablet is 1820.51  
75.31 ng.hours/mL (1461.52 to 2334.98 
ng.hours/mL) and that of reference product is 
1822.09  99.29 ng.hours/mL (1448.28 to 
2728.47 ng.hours/ mL); the mean AUC0-inf 
value of Generic Captopril tablet is 1967.83  
95.65 ng.hours/mL (1529.13 to 2756.40 
ng.hours/mL) and that of reference product is 
1996.94  124.52 ng.hours/mL (1550.27 to 
3213.94 ng.hours/ mL); the mean Cmax value 
for Generic Captopril tablet is found to be 
545.26  22.90 ng/mL (ranging from 421,86 to 
678,73 ng/mL) and that for reference product 
tablet is 548,91  25,07 ng/mL (ranging from 
404,29 to 690,62 ng/mL); and the mean Tmax 
value for Captopril tablet is 1.13  0.08 hours 
(0.75 to 1.5 hours) while that for reference 
product tablet is 1.08  0.08 hours (0.75 to 1.5 
hours). Statistically, these pharmacokinetic 
parameter values for both Generic Captopril 
and reference product are not significantly 
different (P>0.05). 
The values of mean ( SEM) MRT, t1/2, 
Vdss and Cl of captopril in from all subjects 
may be seen in the following table II. Mean 
residence time (MRT), half-life time (t1/2), 
volume of distribution at steady state (Vdss) 
and total clearance (Cl) were presented as a 
Table I. The mean values of Tmax, Cmax and AUC after an oral single dose administration of 50 
mg Generic Captopril and reference tablets in 12 healthy volunteers 
 
No. Parameter Unit 
Product 
Generic Captopril 
Mean  SEM 
Reference product 
Mean  SEM 
1 Tmax hours 1.130.08(*) 1.080.08(*)  
2 Cmax ng/mL 545.2622.90(*) 548.9125.07(*) 
3 AUC0-7 ng.hours/mL 1820.5175.31(*)  1822.0999.29(*)  
4. AUC0-inf ng.hours/mL 1967.8395.65(*)  1996.94124.52(*)  
 
(*) Paired t-test results for all values of both products indicate not significantly different (P>0.05) 
 
Table II. The mean values of MRT, t1/2, Vdss and total clearance after an oral single dose 





 Generic Captopril 
Mean  SEM 
Reference product 
Mean  SEM 
1 MRT hours 2.980.10 (*) 3.100.10 (*) 
2 t1/2 hours 1.680.07 (*) 1.780.06 (*) 
3 Vdss ML 26.011.14 (*) 25.871.25 (*)  
4 Cl mL/hours 76.752.81 (*) 79.503.72 (*) 
 
  (*) Paired t-test results for all values of both products indicate not significantly different (P>0.05) 
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complement. The pharmacokinetic parameter 
values for both Generic Captopril and 
reference tablets are not significantly different 
(P>0.05). 
According to these result, the values of 
Cmax, AUC0-7, AUC0-inf and Tmax (as measures of 
the rate and extent of absorption of captopril, 
respectively) for Generic Captopril and 
reference tablets are not significantly different 
(P>0.05). It indicated that the test products 
(Captopril) are bioequivalent to the reference 
product with respect to the rate and the extent 
of absorption of captopril for 50 mg tablets. 
 
CONCLUSION 
Based on the data, it can be concluded 
that captopril tablets manufactured in 
Indonesia are comparable to foreign brands 
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